Biotech · Private company
Sepul Bio
Track this companyFree. Adds Sepul Bio to your Dealase workspace and tells you when its record changes.
Clinical trials72 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials7
- Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)PHASE3 · RECRUITING · started Jun 4, 2025ClinicalTrials.gov NCT06891443 · fetched Nov 12, 2026
- Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A GenePHASE2 · ACTIVE_NOT_RECRUITING · started Dec 11, 2024ClinicalTrials.gov NCT06627179 · fetched Nov 12, 2026
- Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)PHASE2_PHASE3 · TERMINATED · started Dec 15, 2021ClinicalTrials.gov NCT05176717 · fetched Nov 12, 2026
- Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)PHASE2_PHASE3 · TERMINATED · started Dec 8, 2021ClinicalTrials.gov NCT05158296 · fetched Nov 12, 2026
- An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis PigmentosaPHASE2 · TERMINATED · started Sep 16, 2021ClinicalTrials.gov NCT05085964 · fetched Nov 12, 2026
- Extension Study to Study PQ-110-001 (NCT03140969)PHASE1_PHASE2 · TERMINATED · started May 13, 2019ClinicalTrials.gov NCT03913130 · fetched Nov 12, 2026
- Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 GenePHASE1_PHASE2 · COMPLETED · started Oct 16, 2017ClinicalTrials.gov NCT03140969 · fetched Nov 12, 2026